| Phenotype | The discovery cohort included 1001 patients from the University clinics in Uppsala, Linköping, Karolinska Institute (Stockholm), Lund, and from the four northern-most counties in Sweden. All subjects fulfilled ≥4 ACR-82 classification criteria for SLE and were of European descent.30 Clinical data were collected from the patients’ medical files, including SDI scores, the ACR-82 classification criteria, clinical antiphospholipid syndrome (APS) diagnosis, glomerular filtration rate, chronic kidney disease (CKD) stages, ESRD, renal biopsy data and CVE, defined as myocardial infarction, ischaemic cerebrovascular disease or venous thromboembolism (VTE). Control individuals were healthy blood donors from Uppsala (Uppsala Bioresource) and Lund or population based controls from Stockholm and the four northernmost counties of Sweden. |
| Sample Ancestry | European |
| Total number | 3,803 individuals |
| Detailed numbers |
1,001 cases (26.32%)
2,802 controls
|
| Number of Cohort(s) | 2 |
| Cohort Short Name | Cohort Full Name | Previous/other/additional names (e.g. sub-cohorts) |
|---|---|---|
| Karolinska | Karolinska Institutet | — |
| UHU | University Hospital, Uppsala | — |
The discovery cohort included 1001 patients from the University clinics in Uppsala, Linköping, Karolinska Institute (Stockholm), Lund, and from the four northern-most counties in Sweden